{"brief_title": "Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).", "brief_summary": "This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.", "condition": "Hepatitis C, Chronic", "intervention_type": "Drug", "intervention_name": "Peginterferon alfa-2a [Pegasys]", "description": "180 micrograms sc weekly", "arm_group_label": "Peginterferon Alfa-2a + Ribavirin", "other_name": "Rebetol", "criteria": "Inclusion Criteria: - adult patients at least 18 years of age - CHC infection, genotype 1 - use of 2 forms of contraception during study in both men and women Exclusion Criteria: - previous systemic therapy with anti-viral, anti-neoplastic, or immunomodulatory agents - medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure) - decompensated liver disease - women who are pregnant or breastfeeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00087607.xml"}